Abstract:
The introduction of effective highly active antiretroviral therapy(HAART) in
the mid 1990s led to a marked reduction in the morbidity and mortality of HIV
infection. Side effects of HAART such as dyslipidemia were soon described after its
introduction. It becomes very important to identify dyslipidemia in HIV patients on
antiretroviral therapy for the early detection and prevention of premature coronary
vascular events in such patients.
